Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

PhRMA Rx Marketing Code-Based Safe Harbor Should Be Considered By IG

  • News

Executive Summary

The HHS Inspector General should consider establishing a "safe harbor" provision based on the Pharmaceutical Research & Manufacturers of America's marketing code, the industry association recommended

You may also be interested in...



IG Compliance Guide Approach To CME, Consulting Concerns PhRMA

The Pharmaceutical Research & Manufacturers of America objects to the treatment of manufacturer-sponsored continuing medical education programs in the HHS Office of the Inspector General's final compliance guide

IG Compliance Guide Approach To CME, Consulting Concerns PhRMA

The Pharmaceutical Research & Manufacturers of America objects to the treatment of manufacturer-sponsored continuing medical education programs in the HHS Office of the Inspector General's final compliance guide

Market Share-Based Rebates Are Not Rx Switch Deals, Manufacturers Argue

Drug rebates based on market share and payments to PBMs to disseminate product information are not switching arrangements, a group of 19 manufacturers maintain in comments on the HHS Inspector General's draft compliance guidance

Table

View full table

Tags:
UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By